Wall Street Zen Upgrades Xilio Therapeutics (NASDAQ:XLO) to Buy

Xilio Therapeutics (NASDAQ:XLO) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xilio Therapeutics in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $28.00.

Xilio Therapeutics Stock Performance

Shares of NASDAQ XLO opened at $8.32 on Friday. Xilio Therapeutics has a fifty-two week low of $6.47 and a fifty-two week high of $16.52. The stock has a market cap of $48.09 million, a price-to-earnings ratio of -1.51 and a beta of -0.05. The firm’s 50-day simple moving average is $7.96 and its 200 day simple moving average is $9.56.

Xilio Therapeutics (NASDAQ:XLO) last released its quarterly earnings results on Monday, March 23rd. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.68) by $0.83. The business had revenue of $13.69 million during the quarter, compared to the consensus estimate of $10.90 million. Xilio Therapeutics had a negative return on equity of 393.01% and a negative net margin of 80.05%. On average, sell-side analysts predict that Xilio Therapeutics will post -1.14 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp grew its position in Xilio Therapeutics by 13.7% in the 4th quarter. State Street Corp now owns 186,390 shares of the company’s stock worth $119,000 after purchasing an additional 22,500 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Xilio Therapeutics during the 4th quarter worth approximately $27,000. Squarepoint Ops LLC lifted its position in shares of Xilio Therapeutics by 39.6% during the 3rd quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock worth $277,000 after buying an additional 93,338 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Xilio Therapeutics by 68.3% in the 4th quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock worth $220,000 after buying an additional 139,716 shares during the last quarter. Finally, Velan Capital Investment Management LP purchased a new position in shares of Xilio Therapeutics in the 4th quarter worth approximately $109,000. 54.29% of the stock is currently owned by hedge funds and other institutional investors.

Xilio Therapeutics Company Profile

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.